PPARG and type 2 diabetes mellitus: Thiazolidinediones (TZDs), synthetic insulin-sensitizing PPAR-γ agonists, like rosiglitazone, pioglitazone, and troglitazone, effectively improve IR and lower the blood glucose of T2D patients and have been widely prescribed to treat T2D in the clinic [104].